NC
RDHL

Nexthera Capital’s Redhill Biopharma RDHL Stock Holding History

Nexthera Capital’s Portfolio RDHL Stock Details RDHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-95
Closed -$994K – 46
2016
Q4 		$994K Buy
+95
New +$1.14M 0.58% 32
2016
Q1 		– Sell
-24
Closed -$309K – 41
2015
Q4 		$309K Buy
+24
New +$299K 0.44% 29

Other funds holding RDHL

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
BHB
Bank Hapoalim BM Tel Aviv, Israel $652M AUM 19.01% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PVH
Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return

Nexthera Capital's RDHL Position: Q1 2017 in Review

Nexthera Capital sold out of Redhill Biopharma (RDHL) in Q1 2017, closing a stake of 95 shares — an estimated $994K sold.

Nexthera Capital first reported a position in RDHL in Q4 2015 and held it in 2 quarters. The position peaked at $994K in Q4 2016. 24 funds tracked by Wall St. Rank hold RDHL as of Q1 2017.

  • Nexthera Capital reported no remaining Redhill Biopharma position as of Q1 2017 after selling out during the quarter.
  • Nexthera Capital sold 95 Redhill Biopharma shares in Q1 2017, an estimated $994K.
  • Nexthera Capital first reported a position in Redhill Biopharma in Q4 2015 and held it in 2 quarters.
  • Nexthera Capital's Redhill Biopharma position peaked at $994K in Q4 2016.
  • 24 funds tracked by Wall St. Rank held Redhill Biopharma as of Q1 2017.

Based on Nexthera Capital's 13F filing for Q1 2017, filed 15 May 2017.